- DOT testing covers approximately 12 million safety-sensitive workers across trucking, aviation, rail, transit, maritime, and pipeline industries
- Zero tolerance: any confirmed THC metabolite at or above 15 ng/mL GC-MS confirmation = violation regardless of state cannabis laws
- Immunoassay screening cutoff: 50 ng/mL — confirmed by GC-MS at 15 ng/mL
- Testing occasions include pre-employment, random, post-accident, reasonable suspicion, return-to-duty, and follow-up
- A positive test results in immediate removal from safety-sensitive functions and mandatory SAP (Substance Abuse Professional) evaluation
- Medical cannabis cards provide no protection — federal law governs DOT, not state law
- CBD products are high risk — mislabeled THC content is common and has caused DOT test failures
What Is DOT Drug Testing?
The U.S. Department of Transportation oversees transportation safety across multiple modes and industries through six operating agencies. Each agency has specific regulations governing safety-sensitive employees — workers whose performance directly affects public safety — and requires those employees to participate in federal workplace drug testing programs as a condition of employment.
DOT drug testing is governed by 49 CFR Part 40, the master regulation for DOT drug and alcohol testing procedures. This regulation is supplemented by mode-specific rules from each agency. The testing program uses urine drug tests analyzed by SAMHSA-certified laboratories. A Medical Review Officer (MRO) reviews all results before they are reported to employers.
DOT tests for five drug categories: marijuana (THC), cocaine, amphetamines, opioids, and PCP. Alcohol testing is separate from drug testing but also required under DOT regulations.
Which Industries and Workers Are Covered
| DOT Agency | Industry / Mode | Safety-Sensitive Functions | Approx. Workers |
|---|---|---|---|
| FMCSA | Trucking & buses | CDL drivers operating CMVs over 26,001 lbs, transporting hazmat, or carrying 16+ passengers | ~7 million CDL holders |
| FAA | Aviation | Pilots, co-pilots, flight attendants, air traffic control, aircraft maintenance, flight dispatchers | ~600,000 |
| FRA | Railroad | Engine service, train service, dispatchers, signal maintainers, certain maintenance employees | ~220,000 |
| FTA | Public transit | Bus operators, train operators, vehicle maintenance, transit security, armed personnel | ~340,000 |
| PHMSA | Pipeline | Operations, maintenance, and emergency response on gas and liquid pipelines | ~220,000 |
| USCG | Maritime | Merchant mariners on commercial vessels, towing vessel crew, uninspected passenger vessels | ~200,000 |
DOT Cannabis Testing Cutoffs
DOT urine drug testing for cannabis uses a two-stage process. Initial screening uses an immunoassay (EIA/ELISA) with a 50 ng/mL cutoff for THC metabolites (THC-COOH). Any specimen at or above 50 ng/mL is sent for confirmation testing by gas chromatography/mass spectrometry (GC-MS).
The GC-MS confirmation threshold is 15 ng/mL. A specimen must meet both thresholds to be reported as a confirmed positive: it must screen at ≥50 ng/mL on immunoassay AND confirm at ≥15 ng/mL on GC-MS. A specimen that screens positive but confirms below 15 ng/mL is reported as negative.
These federal cutoffs are lower than some common misconceptions suggest. The 15 ng/mL GC-MS threshold is sensitive enough to detect use within a substantial window for regular users.
Types of DOT Drug Tests
| Testing Occasion | When It Occurs | Key Notes |
|---|---|---|
| Pre-employment | Before beginning safety-sensitive duties | Must receive negative result before performing safety-sensitive functions; no exceptions |
| Random | Unannounced, throughout employment | Computer-generated selection; rates set annually by DOT (cannabis: 50% for FMCSA); test same day as notification |
| Post-accident | Following qualifying accidents | Required within strict time windows post-accident; refusal = violation |
| Reasonable suspicion | When trained supervisor observes specific symptoms | Must be based on articulable observations; supervisor must be trained in detection |
| Return-to-duty | Before resuming safety-sensitive duties after a violation | Must complete SAP evaluation + treatment and receive negative return-to-duty test |
| Follow-up | After return-to-duty, for minimum 12 months | At least 6 unannounced tests in first 12 months; can continue up to 60 months |
What Happens When You Fail a DOT Drug Test
The consequences of a confirmed positive DOT drug test are severe and follow a mandatory sequence defined by 49 CFR Part 40:
| Step | Action | Timeline |
|---|---|---|
| 1 | MRO contacts employee to verify and discuss result | Within the confirmation process |
| 2 | MRO reports verified positive to employer DER (Designated Employer Representative) | Same day as verification |
| 3 | Employer immediately removes employee from all safety-sensitive duties | Immediate upon notification — no grace period |
| 4 | Employee referred to a DOT-qualified Substance Abuse Professional (SAP) | Required before any return-to-duty process |
| 5 | SAP evaluates employee and recommends education or treatment | Variable — weeks to months |
| 6 | Employee completes SAP-recommended treatment | Variable |
| 7 | SAP follow-up evaluation determines return-to-duty readiness | After treatment completion |
| 8 | Negative return-to-duty test required before resuming safety-sensitive duties | Must be negative before reinstatement |
| 9 | Follow-up testing begins (minimum 6 tests in first 12 months) | Continues 1–5 years post-reinstatement |
CDL Drivers: The FMCSA Drug and Alcohol Clearinghouse
Since January 2020, FMCSA operates the Drug and Alcohol Clearinghouse — a federal database that records all DOT drug and alcohol violations for commercial truck and bus drivers. Every carrier must query the Clearinghouse before hiring a CDL driver and must report violations.
A cannabis violation reported to the Clearinghouse remains in a driver’s record and is visible to prospective employers. A driver with a violation is prohibited from performing safety-sensitive duties for any FMCSA-regulated carrier until the return-to-duty process is complete and the record is updated to show the driver is eligible to return. Failing to register in the Clearinghouse process or attempting to work for another carrier without completing the process is a federal violation.
Medical Cannabis: Absolutely No Protection Under DOT
This is the most common misconception among DOT-regulated workers in states with medical or recreational cannabis programs. Federal law governs DOT — not state law. Cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act. There is no medical exception to the DOT drug testing program.
From the FMCSA website: “The use of Schedule I drugs, including marijuana, by CDL holders is prohibited. Federal law does not recognize ‘state-issued marijuana cards.’”
An MRO is specifically prohibited by 49 CFR Part 40 from accepting a medical marijuana explanation as a reason to verify a positive test as negative. Even if an employee presents valid state medical documentation, the MRO must report the positive result.
CBD Products: High Risk for DOT Workers
A growing number of DOT violations have involved workers who used CBD products and tested positive for THC metabolites. The mechanism is straightforward: FDA testing of commercially available CBD products has consistently found that a significant percentage contain THC levels higher than their labels claim. A 2017 study in JAMA found that 26% of CBD products tested contained more THC than labeled, and some contained no CBD at all.
| CBD Product Type | THC Risk Level | Recommendation for DOT Workers |
|---|---|---|
| CBD isolate (99%+ pure CBD, no other cannabinoids) | Low | Lower risk but still no guarantee — verify COA from accredited lab |
| Broad-spectrum CBD (CBD + other cannabinoids, no THC declared) | Medium | High risk — THC often present despite “0 THC” claims; avoid |
| Full-spectrum CBD (whole plant, contains THC) | High | Absolutely avoid — contains THC by design |
| Hemp-derived CBD from poorly regulated sources | Very High | Avoid entirely — no quality assurance |
The official DOT position on CBD: workers who test positive because of CBD product use have no defense. The MRO cannot accept CBD use as an explanation. The violation stands and the return-to-duty process is required. DOT has published guidance explicitly warning workers that they use CBD products at their own risk.
DOT Testing vs. Non-DOT Employer Testing
| Feature | DOT Testing (49 CFR Part 40) | Non-DOT Employer Testing |
|---|---|---|
| Governing law | Federal (DOT regulations) | Employer policy + state law |
| Cannabis cutoff | 50 ng/mL screen / 15 ng/mL GC-MS | Variable (often 50 ng/mL, sometimes 20 ng/mL) |
| Medical cannabis protection | None — zero exceptions | Varies by state (NJ, CT, MN, NY provide some protection) |
| Recreational cannabis protection | None | None in most states; limited in a few |
| Dilute specimen consequence | Mandatory immediate retest under observation | Varies by employer |
| Refusal to test | Treated as positive; immediate removal | Typically treated as positive |
| MRO review | Required for all results | Not always required |
Return-to-Duty and the SAP Process
The Substance Abuse Professional (SAP) is a licensed clinician — physician, licensed clinical social worker, psychologist, employee assistance professional, or certified alcohol/drug counselor — who has completed specific DOT SAP training. The SAP evaluates the employee, recommends an education or treatment program appropriate to the violation, and then conducts a follow-up evaluation to determine whether the employee has complied with recommendations and is ready to return to safety-sensitive duties.
The SAP process cannot be shortened or bypassed. Even if an employer wants the worker back quickly, the worker cannot return to safety-sensitive functions until the SAP follow-up evaluation is complete and a negative return-to-duty test has been collected. The cost of the SAP process is typically the employee’s responsibility and can run $500–$2,000+ depending on the program recommended.
Frequently Asked Questions: DOT Cannabis Testing
Does cannabis legalization in my state protect me from DOT drug test consequences?
No. DOT drug testing is governed by federal law. Cannabis is a Schedule I substance under the federal Controlled Substances Act. Living or working in a state where cannabis is legal — medically or recreationally — provides no protection against a DOT drug test violation. The federal standard applies to all DOT-regulated safety-sensitive workers regardless of state law.
How long after using cannabis can I fail a DOT test?
Detection windows depend heavily on use frequency and body fat percentage. Occasional users (1–2 times per week) may test positive for 7–21 days. Regular daily users can test positive for 30–45 days or longer. Heavy daily users with higher body fat can test positive for 60+ days after last use. The 15 ng/mL GC-MS confirmation threshold is sensitive enough to detect historical use well beyond most users’ estimates.
Can my employer fire me immediately for a positive DOT cannabis test?
An employer must immediately remove a DOT-tested employee from safety-sensitive functions upon receiving a verified positive result. Whether termination follows depends on employer policy. Some employers terminate immediately. Others allow employees to complete the SAP process and potentially return to work. However, the immediate removal from safety-sensitive duties is non-negotiable under 49 CFR Part 40.
Is it safe for CDL drivers to use cannabis during off-duty time in a legal state?
No. There is no “off-duty” exemption in DOT cannabis testing. CDL drivers and other DOT-regulated workers subject to random testing can be selected at any time. THC-COOH detection windows extend days to weeks beyond consumption. Using cannabis recreationally in a legal state while subject to DOT random testing creates real exposure to a career-ending violation.